Omalizumab — CPB 0670 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0670 covering omalizumab (Xolair) and omalizumab-igec (Omlyclo), effective January 5, 2026. Here's what changes for billing teams.

This update to the Aetna omalizumab coverage policy expands covered indications and tightens prescriber specialty requirements across five distinct clinical categories. The policy now explicitly covers IgE-mediated food allergy and immune checkpoint inhibitor-related toxicity — two indications that weren't prominently addressed in earlier versions. If your practice bills for omalizumab under any specialty, this is a coverage policy you need to read before submitting your next claim.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Omalizumab — CPB 0670
Policy Code	CPB 0670
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Allergy/Immunology, Pulmonology, Otolaryngology, Dermatology, Hematology, Oncology
Key Action	Verify prescriber specialty matches indication before submitting prior authorization requests on or after January 5, 2026

---

Aetna Omalizumab Coverage Criteria and Medical Necessity Requirements 2026

CPB 0670 Aetna covers omalizumab for five indications. Each one has its own medical necessity criteria and its own list of acceptable prescriber specialties. That combination is where denials happen — and where your team needs to pay close attention.

Precertification is required for all Aetna participating providers. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277. The site of care utilization management policy also applies, so confirm the administration setting is covered before you schedule the patient.

Asthma (Members 6 Years and Older)

Aetna covers omalizumab for asthma when prescribed by an allergist/immunologist or pulmonologist. There are two paths to approval.

Path 1 — Prior biologic use: The member has received a biologic drug indicated for asthma (e.g., Nucala, Cinqair) within the past year. This is a clean, fast path to approval if you have documentation.

Path 2 — Treatment-naïve to biologics: All six of the following criteria must be met:

One billing note that matters here: Aetna considers baseline total serum IgE measurement medically necessary to establish eligibility and dosing. However, monitoring IgE levels during treatment is not considered medically necessary. Don't bill ongoing IgE monitoring and expect reimbursement — Aetna will deny it. The reason is straightforward: circulating IgE-anti-IgE complexes elevate total IgE readings during therapy, making monitoring clinically meaningless under this policy.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Prescribers must be an allergist/immunologist or otolaryngologist. As with asthma, there are two approval paths: prior biologic use for CRSwNP (e.g., Nucala, Dupixent) in the past year, or meeting the full medical necessity criteria for first-line biologic use.

The prior authorization documentation for CRSwNP typically requires nasal endoscopy findings and CT imaging. Related CPT codes include nasal endoscopy codes 31231, 31233, and 31235, and CT maxillofacial codes 70486, 70487, and 70488. These aren't covered for the omalizumab indication itself — they're the diagnostic workup codes that support your medical necessity documentation. Get those records before you submit the prior auth.

Chronic Spontaneous Urticaria

Allergist/immunologist or dermatologist must prescribe. This is one of Xolair's established FDA indications and generally has cleaner prior authorization outcomes when documentation is complete.

IgE-Mediated Food Allergy

This indication requires an allergist/immunologist. This is a newer explicit coverage category in the Aetna omalizumab coverage policy and one worth flagging. If your allergy practice has been treating IgE-mediated food allergy with omalizumab and struggling with claim denial, the January 5, 2026 update formalizes coverage under CPB 0670. Allergen-specific IgE testing codes — including CPT 86003, 86005, and 86008, as well as the allergy testing series (CPT 95004 through 95074) — are listed as related codes and support the diagnostic record for this indication.

Immune Checkpoint Inhibitor-Related Toxicity

Prescribers for this indication must be a dermatologist, hematologist, or oncologist. This is the most specialized indication in CPB 0670 and the one most likely to generate questions at prior authorization. Your oncology billing team should know this indication exists and that omalizumab billing is now explicitly addressed under this coverage policy.

---

Aetna Omalizumab Exclusions and Non-Covered Indications

CPT 95012 — nitric oxide expired gas determination — is explicitly listed as not covered for indications in CPB 0670. This code is sometimes ordered in complex asthma workups to measure airway inflammation. Aetna does not consider it medically necessary as part of the omalizumab indication criteria.

Ongoing serum IgE monitoring during omalizumab therapy is also not considered medically necessary. Aetna's position here is clinically grounded — but it's a common billing error. Don't include serial IgE monitoring charges in the treatment record expecting reimbursement.

---

Coverage Indications at a Glance

---

Aetna Omalizumab Billing Guidelines and Action Items 2026

These are the steps your billing team needs to take before submitting omalizumab claims under the updated CPB 0670.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Omalizumab Under CPB 0670

Not Covered CPT Codes (Per CPB 0670)

Code	Type	Description Copy
95012	CPT	Nitric oxide expired gas determination